BIOGEN INC. - COMMON STOCK

Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis

07 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody

01 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

31 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

27 Jan 2022 18:50:14 By Nasdaq GlobeNewswire

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®

27 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

04 Jan 2022 07:34:32 By Nasdaq GlobeNewswire

Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

22 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease

20 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Update on Regulatory Submission for Aducanumab in the European Union

17 Dec 2021 06:43:58 By Nasdaq GlobeNewswire

Update on the Phase 4 Confirmatory Study of ADUHELM®

16 Dec 2021 07:00:00 By Nasdaq GlobeNewswire